Loading…
GILD
Gilead Sciences Inc
NASDAQ· Healthcare· Drug Manufacturers - General· CUSIP 375558103
$157.19+2.36%Price as of Oct 23, 00:41 UTC · updated once a day, after the close
At a glance
Gilead Sciences Inc (GILD) is listed on NASDAQ and classified in Drug Manufacturers - General, part of the Healthcare sector. It is headquartered in Foster City, United States and has 17,000 employees. The company is worth $194.91B. Revenue was $29.44B in fiscal 2025, up 2.4% from the year before. Net income was $8.51B. The share price is within 3% of its 52-week high. It pays a dividend yielding 2.09%, and has raised its annual dividend for 9 years in a row in our records. 7 of the 38 superinvestors we track held it at the end of Q2 2026. The largest position belongs to Ken Griffin (Citadel Advisors), at $439.72M. In that quarter, 5 of them opened or added to the position and 2 reduced it. Over the last 30 days, company insiders sold $2.69M of its stock on the open market and bought none. All of those sales were scheduled in advance under 10b5-1 plans.
Written from the data on this page: SEC filings (13F, Form 4, annual reports) and market prices.
Key metrics
- Market cap
- $194.91B
- P/E
- —
- Forward P/E
- 15.8x
- P/B
- 16.5x
- Dividend yield
- 2.09%
- Payout
- —
- EPS
- -$2.65
- ROE
- -20.68%
- Profit margin
- -10.64%
- Revenue growth
- +10.20%
- Beta
- 0.33
- 52-week high
- $160.51
- 52-week low
- $114.02
History
Year by year, from the annual reports; dividends from the payments themselves.
Bars are year-end balances; lines are what happened during the year.
Investors holding this
Major managers that reported this stock in their latest 13F.
Ken GriffinReducedCitadel Advisors · Q2 2026$439.72M3.48M shares · 0.3% of portfolio- Renaissance TechnologiesAddedRenaissance Technologies · Q2 2026$280.14M2.22M shares · 0.4% of portfolio
- Israel EnglanderAddedMillennium Management · Q2 2026$184.32M1.46M shares · 0.1% of portfolio
- Steve CohenAddedPoint72 Asset Management · Q2 2026$181.64M1.44M shares · 0.3% of portfolio
- Cliff AsnessReducedAQR Capital Management · Q2 2026$86.94M695.43K shares · 0.0% of portfolio
- Two SigmaAddedTwo Sigma Investments · Q2 2026$51.7M409.17K shares · 0.0% of portfolio
Ray DalioAddedBridgewater Associates · Q2 2026$36.75M290.88K shares · 0.2% of portfolio
Price over time
▲ +126.6% over 5Y.
today you would have $2,876.62▲ +187.7%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
Indicators, year by year
The last 19 closed years, each at that year’s closing price and reported numbers.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Year-end price | $122.74 | $92.37 | $81.01 | $85.85 | $72.61 | $58.26 | $64.98 | $62.55 | $71.64 | $71.61 | $101.19 | $94.26 | $75.10 | $36.72 | $20.47 | $18.12 | $21.64 | $25.57 | $23.00 | |
| P/E | 15.4x | 18.1x | 243.1x | 18.0x | 23.6x | 14.7x | 582.6x | 15.4x | 15.0x | 20.4x | 7.2x | 8.5x | 12.8x | 41.5x | 22.4x | 11.6x | 10.9x | 15.3x | 24.8x | 28.1x |
| P/S | 3.9x | 5.2x | 4.0x | 3.7x | 3.9x | 3.3x | 3.0x | 3.7x | 3.6x | 3.6x | 3.1x | 4.2x | 5.6x | 10.3x | 5.8x | 3.7x | 3.6x | 5.6x | 8.7x | 10.5x |
| P/B | 5.0x | 6.7x | 6.0x | 4.4x | 5.0x | 4.3x | 4.0x | 3.6x | 3.7x | 4.6x | 5.0x | 7.5x | 9.1x | 10.2x | 6.0x | 4.6x | 4.9x | 6.1x | 10.9x | 11.8x |
| EPS | $6.78 | $0.38 | $4.50 | $3.64 | $4.93 | $0.10 | $4.22 | $4.17 | $3.51 | $9.94 | $11.91 | $7.35 | $1.81 | $1.64 | $1.77 | $1.66 | $1.41 | $1.03 | $0.82 | |
| Dividend yield | 3.40% | 2.57% | 3.33% | 3.70% | 3.40% | 3.91% | 4.67% | 3.88% | 3.65% | 2.90% | 2.57% | 1.27% | — | — | — | — | — | — | — | — |
| Payout | 59.26% | 46.61% | 810.53% | 66.67% | 80.22% | 57.61% | 2720.00% | 59.72% | 54.68% | 59.26% | 18.51% | 10.83% | — | — | — | — | — | — | — | — |
| Profit margin | 27.45% | 28.90% | 1.67% | 20.89% | 16.83% | 22.80% | 0.50% | 23.99% | 24.65% | 17.73% | 44.43% | 55.48% | 48.62% | 27.45% | 26.71% | 33.43% | 36.50% | 37.59% | 37.09% | 37.47% |
| ROE | 29.55% | 37.48% | 2.48% | 24.81% | 21.62% | 29.55% | 0.68% | 23.91% | 25.51% | 22.64% | 71.48% | 97.70% | 78.45% | 27.04% | 27.86% | 41.60% | 49.48% | 41.40% | 46.32% | 42.23% |
Median of the years shown; P/E years above 200x are left out.
Fair price, seven ways
Seven formulas applied to the reported numbers, each with its assumption next to the result. None of them predicts a price.
Earnings
—
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Earnings
—
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Earnings
—
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Earnings
—
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Cash flow
$246.44
Cash flow growing 15.0% a year for 10 years, discounted at 10%, then 2.5% forever.
Operating
$103.74
Sector median of 14.1x operating profit, less net debt. Banks have no EBITDA.
Dividends
$222.25
Dividend growing 5.5% a year against a 7.0% required return, from the stock’s beta.
How the average is calculated
The average of the method families that answered, not of the seven numbers: four of the seven start from the same earnings per share.
Cash flow $246.44+Operating $103.74+Dividends $222.25÷ 3 =$190.81
$190.81
3 methods answered, across 3 families.
$143.11
Room for errors in the reported numbers.
$157.19
+21.4% from the average.
Models, not forecasts, and not investment advice. How each formula works →
Others in the same sector
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| ABTAbbott Laboratories | $102.51 | 37.4x | 3.4x | 2.46% | — | $177.38B |
| NVONovo Nordisk A S | $39.43 | 9.6x | 5.3x | 4.57% | 59.81% | $174.01B |
| PFEPfizer Inc | $30.42 | 40.0x | 2.0x | 5.65% | 5.01% | $173.38B |
| DHRDanaher Corp | $229.75 | 38.7x | 3.0x | 0.70% | 8.19% | $161.51B |
| AMGNAmgen Inc | $447.28 | 27.2x | 20.7x | 2.25% | 91.47% | $241.81B |
| ISRGIntuitive Surgical Inc | $443.85 | 53.7x | 9.6x | 0.00% | 17.93% | $156.8B |
About the company
- 17,000
- Foster City, United States